Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

468 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dipeptidyl peptidase-4 inhibition with linagliptin and effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: Rationale and design of the MARLINA-T2D™ trial.
Groop PH, Cooper ME, Perkovic V, Sharma K, Schernthaner G, Haneda M, Hocher B, Gordat M, Cescutti J, Woerle HJ, von Eynatten M. Groop PH, et al. Among authors: haneda m. Diab Vasc Dis Res. 2015 Nov;12(6):455-62. doi: 10.1177/1479164115579002. Epub 2015 Jul 28. Diab Vasc Dis Res. 2015. PMID: 26224765 Free article. Clinical Trial.
Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial.
Groop PH, Cooper ME, Perkovic V, Hocher B, Kanasaki K, Haneda M, Schernthaner G, Sharma K, Stanton RC, Toto R, Cescutti J, Gordat M, Meinicke T, Koitka-Weber A, Thiemann S, von Eynatten M. Groop PH, et al. Among authors: haneda m. Diabetes Obes Metab. 2017 Nov;19(11):1610-1619. doi: 10.1111/dom.13041. Epub 2017 Jul 31. Diabetes Obes Metab. 2017. PMID: 28636754 Free PMC article. Clinical Trial.
Empagliflozin as add-on to linagliptin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a 52-week, randomized, placebo-controlled trial.
Kawamori R, Haneda M, Suzaki K, Cheng G, Shiki K, Miyamoto Y, Solimando F, Lee C, Lee J, George J. Kawamori R, et al. Among authors: haneda m. Diabetes Obes Metab. 2018 Sep;20(9):2200-2209. doi: 10.1111/dom.13352. Epub 2018 Jun 1. Diabetes Obes Metab. 2018. PMID: 29766636 Free PMC article. Clinical Trial.
Linagliptin as add-on to empagliflozin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a two-part, randomized, placebo-controlled trial.
Kaku K, Haneda M, Tanaka Y, Lee G, Shiki K, Miyamoto Y, Solimando F, Lee J, Lee C, George J. Kaku K, et al. Among authors: haneda m. Diabetes Obes Metab. 2019 Jan;21(1):136-145. doi: 10.1111/dom.13496. Epub 2018 Sep 6. Diabetes Obes Metab. 2019. PMID: 30091172 Free PMC article. Clinical Trial.
Combined changes in albuminuria and kidney function and subsequent risk for kidney failure in type 2 diabetes.
Oshima M, Toyama T, Hara A, Shimizu M, Kitajima S, Iwata Y, Sakai N, Furuichi K, Haneda M, Babazono T, Yokoyama H, Iseki K, Araki SI, Ninomiya T, Hara S, Suzuki Y, Iwano M, Kusano E, Moriya T, Satoh H, Nakamura H, Makino H, Wada T. Oshima M, et al. Among authors: haneda m. BMJ Open Diabetes Res Care. 2021 Jun;9(1):e002311. doi: 10.1136/bmjdrc-2021-002311. BMJ Open Diabetes Res Care. 2021. PMID: 34193460 Free PMC article.
Receptor-Mediated Bioassay Reflects Dynamic Change of Glucose-Dependent Insulinotropic Polypeptide by Dipeptidyl Peptidase 4 Inhibitor Treatment in Subjects With Type 2 Diabetes.
Yanagimachi T, Fujita Y, Takeda Y, Honjo J, Yokoyama H, Haneda M. Yanagimachi T, et al. Among authors: haneda m. Front Endocrinol (Lausanne). 2020 Apr 24;11:214. doi: 10.3389/fendo.2020.00214. eCollection 2020. Front Endocrinol (Lausanne). 2020. PMID: 32390941 Free PMC article.
468 results